Treatment options for advanced pancreatic cancer: a review.

Rahma Warsame, Axel F Grothey

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Advanced pancreatic adenocarcinoma historically has a poor prognosis and the mortality rate has remained unchanged for over a decade. Common treatment options for patients with advanced pancreatic cancer include chemoradiation and/or chemotherapy. Single-agent gemcitabine has been considered the standard of care since 1997. Recently published findings indicate that the oxaliplatin, irinotecan, fluorouracil and leucovorin (FOLFIRINOX) treatment regimen significantly improves overall survival compared with gemcitabine. Research has shifted to focus on understanding the causes the resistance of pancreatic cancer to chemotherapy and potential methods to overcome it. This review will focus on the current treatment options, the evolution of targeted therapy, novel agents on the horizon and potential options to ameliorate chemoresistance.

Original languageEnglish (US)
Pages (from-to)1327-1336
Number of pages10
JournalExpert Review of Anticancer Therapy
Volume12
Issue number10
StatePublished - Oct 2012

Fingerprint

gemcitabine
Pancreatic Neoplasms
irinotecan
oxaliplatin
Drug Therapy
Leucovorin
Therapeutics
Standard of Care
Fluorouracil
Adenocarcinoma
Survival
Mortality
Research

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Treatment options for advanced pancreatic cancer : a review. / Warsame, Rahma; Grothey, Axel F.

In: Expert Review of Anticancer Therapy, Vol. 12, No. 10, 10.2012, p. 1327-1336.

Research output: Contribution to journalArticle

Warsame, R & Grothey, AF 2012, 'Treatment options for advanced pancreatic cancer: a review.', Expert Review of Anticancer Therapy, vol. 12, no. 10, pp. 1327-1336.
Warsame, Rahma ; Grothey, Axel F. / Treatment options for advanced pancreatic cancer : a review. In: Expert Review of Anticancer Therapy. 2012 ; Vol. 12, No. 10. pp. 1327-1336.
@article{c60f79c1442f46bd9ee33746fcc410e5,
title = "Treatment options for advanced pancreatic cancer: a review.",
abstract = "Advanced pancreatic adenocarcinoma historically has a poor prognosis and the mortality rate has remained unchanged for over a decade. Common treatment options for patients with advanced pancreatic cancer include chemoradiation and/or chemotherapy. Single-agent gemcitabine has been considered the standard of care since 1997. Recently published findings indicate that the oxaliplatin, irinotecan, fluorouracil and leucovorin (FOLFIRINOX) treatment regimen significantly improves overall survival compared with gemcitabine. Research has shifted to focus on understanding the causes the resistance of pancreatic cancer to chemotherapy and potential methods to overcome it. This review will focus on the current treatment options, the evolution of targeted therapy, novel agents on the horizon and potential options to ameliorate chemoresistance.",
author = "Rahma Warsame and Grothey, {Axel F}",
year = "2012",
month = "10",
language = "English (US)",
volume = "12",
pages = "1327--1336",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "10",

}

TY - JOUR

T1 - Treatment options for advanced pancreatic cancer

T2 - a review.

AU - Warsame, Rahma

AU - Grothey, Axel F

PY - 2012/10

Y1 - 2012/10

N2 - Advanced pancreatic adenocarcinoma historically has a poor prognosis and the mortality rate has remained unchanged for over a decade. Common treatment options for patients with advanced pancreatic cancer include chemoradiation and/or chemotherapy. Single-agent gemcitabine has been considered the standard of care since 1997. Recently published findings indicate that the oxaliplatin, irinotecan, fluorouracil and leucovorin (FOLFIRINOX) treatment regimen significantly improves overall survival compared with gemcitabine. Research has shifted to focus on understanding the causes the resistance of pancreatic cancer to chemotherapy and potential methods to overcome it. This review will focus on the current treatment options, the evolution of targeted therapy, novel agents on the horizon and potential options to ameliorate chemoresistance.

AB - Advanced pancreatic adenocarcinoma historically has a poor prognosis and the mortality rate has remained unchanged for over a decade. Common treatment options for patients with advanced pancreatic cancer include chemoradiation and/or chemotherapy. Single-agent gemcitabine has been considered the standard of care since 1997. Recently published findings indicate that the oxaliplatin, irinotecan, fluorouracil and leucovorin (FOLFIRINOX) treatment regimen significantly improves overall survival compared with gemcitabine. Research has shifted to focus on understanding the causes the resistance of pancreatic cancer to chemotherapy and potential methods to overcome it. This review will focus on the current treatment options, the evolution of targeted therapy, novel agents on the horizon and potential options to ameliorate chemoresistance.

UR - http://www.scopus.com/inward/record.url?scp=84877087883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877087883&partnerID=8YFLogxK

M3 - Article

C2 - 23176620

AN - SCOPUS:84877087883

VL - 12

SP - 1327

EP - 1336

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 10

ER -